Author Manuscript Gastroenterology. Author manuscript; available in PMC 2015 May 01.
|
|
- Joleen Greer
- 5 years ago
- Views:
Transcription
1 NIH Public Access Author Manuscript Published in final edited form as: Gastroenterology May ; 146(5): e5. doi: /j.gastro Risk of Colorectal Cancer for Carriers of Mutations in MUTYH, with and without a Family History of Cancer Aung Ko Win 1, James G. Dowty 1, Sean P. Cleary 2,3, Hyeja Kim 2,3, Daniel D. Buchanan 4, Joanne P. Young 4, Mark Clendenning 4, Christophe Rosty 4,5,6, Robert J. MacInnis 1,7, Graham G. Giles 1,7, Alex Boussioutas 8,9,10, Finlay A. Macrae 11, Susan Parry 12,13, Jack Goldblatt 14, John A. Baron 15, Terrilea Burnett 16, Loïc Le Marchand 16, Polly A. Newcomb 17, Robert W. Haile 18, John L. Hopper 1, Michelle Cotterchio 3, Steven Gallinger 2,3, Noralane M. Lindor 19, Katherine M. Tucker 20, Ingrid M. Winship 8,21, and Mark A. Jenkins 1 1 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Parkville, Victoria, Australia. 2 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. 3 Cancer Care Ontario, Toronto, Ontario, Canada. 4 Cancer and Population Studies Group, Queensland Institute of Medical Research, Bancroft Centre, Herston, Queensland, Australia. 5 Department of Molecular and Cellular Pathology, University of Queensland, Herston, Queensland, Australia. 6 Envoi Specialist Pathologists, Herston, Queensland, Australia. 7 Cancer Epidemiology Centre, Cancer Council Victoria, Carlton, Victoria, Australia. 8 Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia. 9 Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. 10 Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. 11 Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, Victoria, Australia. 12 New Zealand Familial Gastrointestinal Cancer Registry, Auckland City Hospital, Auckland, New Zealand. 13 Department of Gastroenterology, Middlemore Hospital, Auckland, New Zealand New Zealand. 14 Genetic Services & Familial Cancer Program of Western Australia and School of Paediatrics and Child Health, University of Western Australia, Perth, Australia 15 Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 16 University of Hawaii Cancer Center, Honolulu, Hawaii, USA. 17 Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 18 Department of Medicine, Division of Oncology, Stanford University, California, USA. 19 Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona, USA. 20 Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, New South Wales, Australia. 21 Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Australia Abstract We studied 2332 individuals with monoallelic mutations in MUTYH among 9504 relatives of 264 colorectal cancer (CRC) cases with a MUTYH mutation. We estimated CRC risks, through 70 y of age, of 7.2% for male carriers of monoallelic mutations (95% confidence interval [CI], 4.6% 11.3%) and 5.6% for female carriers of monoallelic mutations (95% CI, 3.6% 8.8%), irrespective of family history. For monoallelic MUTYH mutation carriers with a first-degree relative with CRC, diagnosed by 50 y of age who does not have the MUTYH mutation, risks of CRC were 12.5% for men and (95% CI, 8.6% 17.7%) and 10% for women (95% CI, 6.7% 14.4%). Risks of
2 2014 The American Gastroenterological Association. Published by Elsevier Inc. All rights reserved. Win et al. Page 2 Corresponding author, Mark Jenkins, PhD, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population and Global Health, Level 3, 207 Bouverie Street, The University of Melbourne, VIC 3010 Australia, Tel: CRC 0902; Fax: for +61 carriers of 5815, monoallelic m.jenkins@unimelb.edu.au. mutations MUTYH with a first-degree relative with CRC are Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. DISCLAIMER The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR. Authors had full responsibility for the design of the study, the collection of the data, the analysis and interpretation of the data, the decision to submit the manuscript for publication, and the writing of the manuscript. DISCLOSURE The authors have no conflict of interest to declare with respect to this manuscript. Authors Contributions Aung Ko Win: study concept and design; acquisition of data; statistical analysis; interpretation of data; drafting and critical review of the manuscript for important intellectual content; James G. Dowty: study concept and design; statistical analysis; interpretation of data; drafting and critical review of the manuscript for important intellectual content; Sean P. Cleary: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; approval of the final version of the manuscript Hyeja Kim: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; approval of the final version of the manuscript Daniel D. Buchanan: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Joanne P. Young: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Mark Clendenning: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Christophe Rosty: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Robert J. MacInnis: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Graham G. Giles: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Alex Boussioutas: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Finlay A. Macrae: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Susan Parry: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; approval of the final version of the manuscript Jack Goldblatt: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; approval of the final version of the manuscript John A. Baron: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; approval of the final version of the manuscript Terrilea Burnett: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Loïc Le Marchand: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Polly A. Newcomb: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Robert W. Haile: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; John L. Hopper: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Michelle Cotterchio: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Steven Gallinger: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Noralane M. Lindor: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Katherine M. Tucker: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Ingrid M. Winship: acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content; Mark A. Jenkins: study concept and design; acquisition of data; interpretation of data; critical review of the manuscript for important intellectual content;
3 Win et al. Page 3 sufficiently high to warrant more intensive screening than for the general population. Keywords colon cancer; genetics; base excision repair gene; DNA damage response RESULTS MUTYH is a base excision repair gene that detects and protects against oxidative DNA damage. 1 Individuals with germline mutations in both alleles (biallelic mutation carriers), whether they are homozygotes or compound heterozygotes, develop MUTYH-associated polyposis, an autosomal recessive disorder with substantially increased risk of CRC. 2 Individuals with germline mutations in one allele (monoallelic mutation carriers) have a small increased risk of CRC 3 5. Due to the rarity of these mutations, 4, 6 previous studies have had limited ability to provide precise estimates of age- and sex-specific CRC risks for MUTYH mutation carriers. Further, the variability in CRC risk between carriers has not been quantified. Modelling of this variability can indicate a potential role for modifiers of risk. We identified 9504 relatives (4613 females) from the families of the 264 (236 populationbased and 28 clinic-based) probands with a monoallelic or biallelic MUTYH mutation from the Colon Cancer Family Registry; 138 (52%) from USA, 81 (31%) from Canada, and 45 (17%) from Australia and New Zealand. In the relatives, we observed 261 CRCs (114 females) whose ages at diagnosis had a median of 65 (range 26 98) years. MUTYH mutation status was known for 340 relatives (13 biallelic mutation carriers, 142 monoallelic mutation carriers, and 185 non-carriers). We estimated an additional 43 biallelic and 2190 monoallelic mutation carriers among non-genotyped relatives, giving a total estimated number of 56 biallelic and 2332 monoallelic mutation-carrying relatives in our sample. Our methods allowed for CRC risk estimation in mutation families to be due to the MUTYH mutation as well as polygenic factors (combination of a large number of CRC-associated genetic susceptibility loci). 7 We estimated CRC risks, through 70y of age, for male and female to be: 75.4% (95%CI, 41.2% 96.6%) and 71.7% (95%CI, 44.5% 92.1%), respectively, for biallelic mutation carriers, and 7.2% (95%CI, 4.6% 11.3%) and 5.6% (95%CI, 3.6% 8.8%), respectively, for monoallelic mutation carriers (Figure 1). The estimated CRC risks, through 70y of age, for monoallelic mutation carriers with a firstdegree relative with CRC were similar whether the relative was untested or a non-carrier or a monoallelic mutation carrier: approximately 12% (95%CI, 9% 18%) and 10% (95%CI, 7% 14%) respectively for males and females in comparison with males and females from the general population (2.9% and 2.1% respectively). However, if their affected first-degree relative was a biallelic mutation carrier then risks of CRC, through 70y of age, for monoallelic mutation carriers was estimated to be 10.4% (95%CI, 7.0% 15.0%) and 8.2% (95%CI, 5.4% 12.0%) respectively for males and females (Table 1). In addition, we estimated CRC risks for six other scenarios (Supplementary Figure 1). The highest risk of CRC for a monoallelic mutation carrier corresponded to having two affected first-degree relatives: one is a biallelic mutation carrier and one is a noncarrier (Supplementary Figure 1C).
4 Win et al. Page 4 DISCUSSION We found no evidence for a difference in hazard ratios of CRC for biallelic mutation carriers between males and females (108 (95%CI, ) vs 129 (95%CI, ); p=0.85), nor for monoallelic mutation carriers between males and females (2.46 (95%CI, ) vs 2.67 (95%CI, ); p=0.81). Hazard ratio of CRC for Y179C monoallelic carriers was higher than for G396D monoallelic carriers (4.81 (95%CI, ) vs 2.42 (95%CI, ); p=0.05), but there was no difference between biallelic carriers of Y179C and G396D (p=0.84) (Supplementary Table 1). The standard deviation of the polygenic component was estimated to be 1.11 ( , p<0.001); see the Materials and Methods for a general formula relating this standard deviation to the hazard ratio. At ages less than 50y this formula reduces to Pharoah s formula for early-onset disease 7 and says that monoallelic MUTYH mutation carriers with an affected first-degree relative have CRC incidences approximately 4.58 (for males) or 4.97 (for females) times the population incidences. However, Supplementary Figure 2 gives precise hazard ratios for all ages and shows that by age 70y, Pharoah s formula overestimates relative risks by roughly 30%. Our finding of almost complete penetrance for biallelic MUTYH mutation carriers is consistent with previous studies There is some evidence that biallelic mutation carriers move rapidly along a mutator phenotype progression to cancer. 11 These findings support the recommendation that biallelic mutation carriers should consider prophylactic total colectomy with ileorectal anastomosis depending on the individual, age of presentation and number and size of polyps present. 12 We estimated monoallelic mutation carriers had on average, an approximately 2.5-fold increased risk of CRC compared with the general population, consistent with one previous study. 13 This level of increased risk for monoallelic mutation carriers is similar to that for people with a first-degree relative with CRC, who are recommended 5-yearly colonoscopy starting 10y younger than the youngest case in the family and before age 50y. 13 However, monoallelic mutation carriers who have an affected first-degree relative were at approximately 5-fold increased risk. For these carriers, colonoscopy beginning at age 40y, with follow-up at intervals dependent on the presence or absence of polyps but no less often than every 5 years, may be reasonable. We observed strong evidence that CRC risks for carriers are highly heterogeneous. The observed heterogeneity in risk could also be caused by environmental factors shared between family members or by differences in risk between mutations. To our knowledge, thus far the only study investigating modifiers of CRC risks for MUTYH mutation carriers was on the relationship with hormone replacement therapy, which reported no evidence of interaction between hormone replacement therapy and MUTYH mutations. 3 In this study of 12 variants of MUTYH mutations, 93% of the MUTYH mutations were Y179C and G396D (Supplementary Table 2); consistent with a previous study of Caucasians. 14 We found CRC risk was higher for monoallelic carriers of Y179C than for
5 Win et al. Page 5 G396D; consistent with previous studies. 3, 15 However, given our approach of genotyping for 12 mutations by MS and WAVE followed by confirmatory Sanger sequencing of MUTYH in carriers (Materials and Methods), there is the possibility that we missed other pathogenic mutations in MUTYH that were not one of the 12 mutations genotyped. Although we identified additional variants from Sanger sequencing, their pathogenicity was considered inconclusive (unclassified variants) and therefore not included in this analysis. Additional MUTYH mutations may reside in different ethnic groups however this cohort was predominantly Caucasian. We used sophisticated statistical techniques to adjust for ascertainment, to account for residual familial aggregation of disease and therefore avoid bias, and to use data for all family members, whether genotyped or not, and therefore maximized statistical power and avoided survival bias. In conclusion, using the largest international study to date we have produced unbiased estimates of CRC risks for MUTYH mutation carriers which are the most precise and reliable currently available. In addition to the confirmed very high risk of CRC to biallelic MUTYH mutation carriers, CRC risk for monoallelic mutation carriers depends on family history and can be sufficiently high to warrant consideration of more intensive CRC screening than for the general population. Supplementary Material Acknowledgments Refer to Web version on PubMed Central for supplementary material. The authors thank all study participants of the Colon Cancer Family Registry and staff for their contributions to this project. FUNDING REFERENCES This work was supported by the National Cancer Institute, National Institutes of Health under RFA #CA and through cooperative agreements with members of the Colon Cancer Family Registry and Principal Investigators. Collaborating centers include Australasian Colorectal Cancer Family Registry (U01 CA097735), Familial Colorectal Neoplasia Collaborative Group (U01 CA074799) [USC], Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783), Seattle Colorectal Cancer Family Registry (U01 CA074794), and University of Hawaii Colorectal Cancer Family Registry (U01 CA074806). This work was also supported by a grant from the National Cancer Institute, USA (R01CA170122) and a Centre for Research Excellence grant from the National Health and Medical Research Council (NHMRC), Australia (APP ). AKW is supported by the Picchi Brothers Foundation Cancer Council Victoria Cancer Research Scholarship, Australia. MAJ is an NHMRC Senior Research Fellow. JLH is a NHMRC Senior Principal Research Fellow. CR is a Jass Pathology Fellow. 1. Al-Tassan N, et al. Nat Genet. 2002; 30:227. [PubMed: ] 2. Cleary SP, et al. Gastroenterology. 2009; 136: [PubMed: ] 3. Theodoratou E, et al. Br J Cancer. 2010; 103: [PubMed: ] 4. Win AK, et al. Fam Cancer. 2011; 10:1 9. [PubMed: ] 5. Win AK, et al. Int J Cancer. 2011; 129: [PubMed: ] 6. Grover S, Kastrinos F, et al. JAMA. 2012; 308: [PubMed: ]
6 Win et al. Page 6 7. Pharoah PDP, et al. Nat Genet. 2002; 31: [PubMed: ] 8. Lubbe SJ, et al. J Clin Oncol. 2009; 27: [PubMed: ] 9. Farrington SM, Tenesa A, et al. Am J Hum Genet. 2005; 77: [PubMed: ] 10. Nieuwenhuis MH, et al. Gut. 2012; 61: [PubMed: ] 11. Macrae F, et al. Gut. 2013; 62: [PubMed: ] 12. Buecher B, et al. Fam Cancer. 2012; 11: [PubMed: ] 13. Jones N, et al. Gastroenterology. 2009; 137: [PubMed: ] 14. Cheadle JP, Sampson JR. DNA Repair. 2007; 6: [PubMed: ] 15. Balaguer F, et al. Clin Gastroenterol Hepatol. 2007; 5: [PubMed: ]
7 Win et al. Page 7
8 Win et al. Page 8 Figure 1. Cumulative risk of colorectal cancer for (A) male and (B) female MUTYH mutation carriers. Note that the risks for a monoallelic carrier with an affected firstdegree relative (FDR) who is either untested, a noncarrier or a monoallelic carrier are virtually identical (see Table 1) so the unbroken, darker grey lines cannot be distinguished in the figure.
9 Win et al. Page 9 Table 1 Cumulative risks (95% confidence intervals) of colorectal cancer for biallelic and monoallelic MUTYH mutation carriers Age (years) General population Biallelic mutation carriers irrespective of family history irrespective of family history with untested FDR diagnosed at 50 years Monoallelic mutation carriers with non-carrier FDR diagnosed at 50 years with monoallelic FDR diagnosed at 50 years with bialleic FDR diagnosed at 50 years Male ( ) 0 (0 0.1) 0.1 ( ) 0.1 (0 0.1) 0.1 (0 0.1) 0.1 (0 0.1) ( ) 0.2 ( ) 0.4 ( ) 0.4 ( ) 0.4 ( ) 0.3 ( ) ( ) 0.8 ( ) 1.6 ( ) 1.6 ( ) 1.6 ( ) 1.3 ( ) ( ) 2.8 ( ) 5.2 ( ) 5.2 ( ) 5.2 ( ) 4.2 ( ) ( ) 7.2 ( ) 12.4 ( ) 12.5 ( ) 12.4 ( ) 10.4 ( ) ( ) 13.6 ( ) 22.2 ( ) 22.3 ( ) 22.2 ( ) 19.1 ( ) Female ( ) 0 (0 0.1) 0.1 ( ) 0.1 ( ) 0.1 ( ) 0.1 (0 0.1) ( ) 0.2 ( ) 0.4 ( ) 0.4 ( ) 0.4 ( ) 0.3 ( ) ( ) 0.8 ( ) 1.5 ( ) 1.5 ( ) 1.5 ( ) 1.2 ( ) ( ) 2.3 ( ) 4.3 ( ) 4.3 ( ) 4.3 ( ) 3.5 ( ) ( ) 5.6 ( ) 9.9 ( ) 10 ( ) 9.9 ( ) 8.2 ( ) ( ) 10.9 (7 16.8) 18.2 ( ) 18.3 ( ) 18.2 ( ) 15.4 ( ) FDR, first-degree relative; CRC, colorectal cancer.
IJC International Journal of Cancer
IJC International Journal of Cancer Lynch syndrome and cervical cancer Yoland C. Antill 1, James G. Dowty 2, Aung Ko Win 2, Tina Thompson 3, Michael D. Walsh 4, Margaret C. Cummings 5, Steven Gallinger
More informationRisk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers
Ann Surg Oncol (2013) 20:1829 1836 DOI 10.1245/s10434-012-2858-5 ORIGINAL ARTICLE COLORECTAL CANCER Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation
More informationMultivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome
International Journal of Epidemiology, 2016, 940 953 doi: 10.1093/ije/dyw036 Advance Access Publication Date: 10 April 2016 Original article Other Health-related Behaviours and Cancer Multivitamin, calcium
More informationAnalysis of current testing practices
Clin Genet 2015: 87: 368 372 Printed in Singapore. All rights reserved Short Report Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis 2014 John Wiley & Sons
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationColorectal cancer (CRC) is the third most common
GASTROENTEROLOGY 2009;136:1251 1260 Germline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study SEAN P. CLEARY,*,, MICHELLE COTTERCHIO,, MARK A. JENKINS, HYEJA KIM,* ROBERT
More informationColorectal cancer and self-reported tooth agenesis
Lindor et al. Hereditary Cancer in Clinical Practice 2014, 12:7 RESEARCH Open Access Colorectal cancer and self-reported tooth agenesis Noralane M Lindor 1*, Aung Ko Win 2, Steven Gallinger 3, Darshana
More informationIdentification of Lynch Syndrome Among Patients With Colorectal Cancer JAMA. 2012;308(15): all these tumors. It is an autosomaldominant
ORIGINAL CONTRIBUTION Identification of Lynch Syndrome Among Patients With Colorectal Cancer Leticia Moreira, MD Francesc Balaguer, MD, PhD Noralane Lindor, MD Albert de la Chapelle, MD, PhD Heather Hampel,
More informationbreast cancer; relative risk; risk factor; standard deviation; strength of association
American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationExtensive Surgery in LS factoring in gene and gender. Gabriela Möslein
Extensive Surgery in LS factoring in gene and gender Gabriela Möslein Where we are coming from. Non polyposis colon cancer Recommend subtotal colectomy at the time of the first colon cancer Recommend prophylactic
More informationAccepted Manuscript. Utility of Genetic Testing in Persons with Multiple Colorectal Polyps. Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS
Accepted Manuscript Utility of Genetic Testing in Persons with Multiple Colorectal Polyps Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS PII: S1542-3565(19)30259-9 DOI: https://doi.org/10.1016/j.cgh.2019.03.007
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2018 Origination: 1/2004 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationHorizon Scanning Series The Future of Precision Medicine in Australia
Horizon Scanning Series The Future of Precision Medicine in Australia Precision medicine to become standard practice, not a specialty This input paper was prepared by Professor Ingrid Winship (Melbourne
More informationPerformance of PREMM 1,2,6 detecting Lynch syndrome among endometrial cancer cases
American College of Medical Genetics and Genomics Performance of, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases Rowena C. Mercado, MD, MPH 1, Heather Hampel, MS 2, Fay
More informationBMJ Open. Germline Mutations in PMS2 and MLH1 in Individuals with Solitary Loss of PMS2 Expression in Colorectal Carcinomas
Germline Mutations in PMS and MLH in Individuals with Solitary Loss of PMS Expression in Colorectal Carcinomas Journal: Manuscript ID bmjopen-0-0 Article Type: Research Date Submitted by the Author: 0-Oct-0
More informationN.Z.F.G.I.C.S, S.P.S., N.B.S.P. Abbreviating bowel cancer in New Zealand: the journey
N.Z.F.G.I.C.S, S.P.S., N.B.S.P. Abbreviating bowel cancer in New Zealand: the journey Susan Parry Gastroenterologist National Medical Lead, NZ Familial Gastrointestinal Cancer Service, Auckland Hospital
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationShould the grading of colorectal adenocarcinoma include microsatellite instability status?
Accepted Manuscript Should the grading of colorectal adenocarcinoma include microsatellite instability status? Christophe Rosty MD PhD FRCPA, Elizabeth J. Williamson PhD, Mark Clendenning PhD, Rhiannon
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationInherited factors contribute to an estimated 35% of
GASTROENTEROLOGY 2009;137:489 494 Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH NATALIE JONES,* STEFANIE VOGT, MAARTJE NIELSEN, DARIA CHRISTIAN, PETRA A.
More informationAccepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A.
Accepted Manuscript En bloc resection for 10-20 mm polyps to reduce post-colonoscopy cancer and surveillance C. Hassan, M. Rutter, A. Repici PII: S1542-3565(19)30412-4 DOI: https://doi.org/10.1016/j.cgh.2019.04.022
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2019 Origination: 1/2004 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas
More informationGENOMICS, ACRONYMS, AND UNDERSTANDING: TRANSLATING GENETICS RESEARCH FROM CANCER FAMILY REGISTRIES TO BEHAVIORAL MEDICINE
GENOMICS, ACRONYMS, AND UNDERSTANDING: TRANSLATING GENETICS RESEARCH FROM CANCER FAMILY REGISTRIES TO BEHAVIORAL MEDICINE Sherri Sheinfeld Gorin (Chair), Deb Bowen on behalf of the Behavioral Working Group
More informationHow common are mutations in the MSH2 gene? 1. Mutations that cause Lynch syndrome are rare found in approximately 1 in 370 individuals.
The gene is a tumor suppressor gene. Tumor suppressor genes slow down cell division, repair DNA mistakes, or tell cells when to die. When they don't work properly, cells can grow out of control, which
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationPathology reports, related operative reports and consult letters must be provided with a request for assessment.
Page 1 of 6 Polyposis Syndromes Inherited risk for colorectal cancer is associated with a number of polyposis syndromes (genes), some of which are well-defined and others are less common. Identification
More informationManaging Moderate Penetrance
Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationTHE PRESENCE OF MULTIPLE COlorectal
ORIGINAL CONTRIBUTION Prevalence and Phenotypes of APC and MUTYH Mutations in Patients With Multiple Colorectal Adenomas Shilpa Grover, MD, MPH Fay Kastrinos, MD, MPH Ewout W. Steyerberg, PhD E. Francis
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationIncreasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients
Accepted Manuscript Increasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients George Cholankeril, MD, Andrew A. Li, MD, Brittany B. Dennis, PhD, Alice E. Toll, MS, Donghee
More informationCaring for Patients at Risk for Hereditary Colorectal Cancer
February 05, 2007 By Karen Greco, PhD, RN, ANP [1] About 6% of colorectal cancers are caused by genetic mutations associated with hereditary colorectal cancer syndromes. The most common hereditary cancer
More informationPMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table
PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Genetic Testing for Inherited Susceptibility to Colon Cancer Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Genetic Testing for Inherited Susceptibility
More information2018 National Academy of Medicine Annual Meeting
2018 National Academy of Medicine Annual Meeting October 15, 2018 Targeting Cancer with Precision Prevention Ernest Hawk, M.D., M.P.H. What is Precision Prevention? The concept of precision medicine prevention
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationHRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years
HRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years Frank A. Firgaira, Ram Seshadri, Christopher R. E. McEvoy, Gillian S. Dite, Graham G. Giles, Margaret R. E.
More informationTitle: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease
Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease Authors: Jesús Castro, Miriam Cuatrecasas, Francesc Balaguer, Elena Ricart, María Pellisé DOI: 10.17235/reed.2017.5068/2017
More informationMr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationGenetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes
Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes Policy Number: 2.04.08 Last Review: 1/2014 Origination: 1/2004 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Lynch Syndrome and Other Inherited Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Lynch Syndrome and Other
More informationBreast cancer risk prediction using a polygenic risk score in the familial setting: a
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kconfab Hongyan Li 1 MSc, Bingjian Feng 2 PhD, Alexander
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative
More informationA Multistate Frailty Model for Sequential Events from a Family-based Study
A Multistate Frailty Model for Sequential Events from a Family-based Study Yun-Hee Choi 1 & Balakumar Swaminathan 2 1 Department of Epidemiology and Biostatistics, Western University, London, Ontario,
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Roles in and barriers to metabolic screening for people taking antipsychotic medications: A survey of psychiatrists Permalink https://escholarship.org/uc/item/6xh6w409
More informationACG Clinical Guideline: Colorectal Cancer Screening
ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,
More informationFAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry
FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationAccepted Manuscript. Prebiotics Versus Low Fodmap Diet: An Interpretative Nightmare. Jane Varney, Jane G. Muir, Peter R. Gibson
Accepted Manuscript Prebiotics Versus Low Fodmap Diet: An Interpretative Nightmare Jane Varney, Jane G. Muir, Peter R. Gibson PII: S0016-5085(18)35389-7 DOI: https://doi.org/10.1053/j.gastro.2018.10.060
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationGI Screening/Surveillance in Lynch Syndrome
GI Screening/Surveillance in Lynch Syndrome M Appleyard Royal Brisbane and Women s Hospital Brisbane, Australia GI Disease and Lynch Syndrome What are risks of GI disease in Lynch? Who do we screen for
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.08 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date January 30, 2015 Original Policy Date October
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationPathology perspective of colonic polyposis syndromes
Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General
More informationMSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table
MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationSupplementary Figure 1. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations.
Supplementary Figure. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations. a Eigenvector 2.5..5.5. African Americans European Americans e
More informationSocial determinants of colorectal cancer screening, treatment and outcomes in the Colon-CFR
Adams Scott 2010 C-EX-1209-01 Impact of Inflammatory Bowel Disease on CRC Mortality Ahnen Dennis 2001 C-LA-0101-01 Family History Characteristics in the Colon CFRs University of Colorado School of Medicine
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationResult Navigator. Positive Test Result: BMPR1A. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: BMPR1A Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationarticle MATERIALS AND METHODS
September 2006 Vol. 8 No. 9 article Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention Scott D. Ramsey, MD, PhD 1,2, Paula Yoon, ScD,
More informationGuidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
s on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer Francis M. Giardiello, MD, 1 John I. Allen, 2 Jennifer E. Axilbund,
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationGenetic Testing for Inherited Susceptibility to Colon Cancer; Including Microsatellite Instability Testing. Original Policy Date
MP 2.04.06 Genetic Testing for Inherited Susceptibility to Colon Cancer; Including Microsatellite Instability Testing Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationPost-colonoscopy colorectal cancers in Lynch syndrome
Post-colonoscopy colorectal cancers in Lynch syndrome Francesc Balaguer, MD PhD High Risk Colorectal Cancer Clinic Head of the Gastroenterology Department Hospital Clínic de Barcelona fprunes@clinic.cat
More informationGI Polyp syndromes in children. Screening and surveillance, surgery.
Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital, UK GI Polyp syndromes in children Screening and surveillance, surgery. No conflict of interests to declare Objectives Understand
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationPancreas Cancer Genomics
Pancreas Cancer Genomics Steven Gallinger MD, MSc, FRCS HPB Surgical Oncology Program University Health Network Samuel Lunenfeld Research Institute Mount Sinai Hospital University of Toronto Fate of the
More informationCascade Genetic Testing in Families with Lynch Syndrome. Elena M. Stoffel MD MPH University of Michigan January 26, 2016
Cascade Genetic Testing in Families with Lynch Syndrome Elena M. Stoffel MD MPH University of Michigan January 26, 2016 Cascade Genetic Screening An active process to find relatives of patients affected
More informationPALB2 mutations in European familial pancreatic cancer families
Clin Genet 2010: 78: 490 494 Printed in Singapore. All rights reserved Short Report 2010 John Wiley & Sons A/S CLINICAL GENETICS doi: 10.1111/j.1399-0004.2010.01425.x PALB2 mutations in European familial
More informationColorectal Polyps in Carriers of the APC I1307K Polymorphism
Colorectal Polyps in Carriers of the APC I1307K Polymorphism Gad Rennert, M.D., Ph.D., 1 Ronit Almog, M.D., M.P.H., 1 Lynn P. Tomsho, B.S., 2,3 Marcelo Low, M.P.H., 1 Mila Pinchev, M.D., 1 Yoram Chaiter,
More informationCarol A. Burke, MD, FACG
Updated Guidelines for CRC C Screening and Surveillance Carol A. Burke MD, FACG, FASGE, FACP Cleveland Clinic, Cleveland, OH Gastroenterology t 2012;143:844 143 Gut 2010;59:666 1 Caveat for all Recommendations
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2018 Related Policies: None Genetic Testing for PTEN Hamartoma Tumor Syndrome Description The PTEN hamartoma tumor syndrome (PHTS) includes several syndromes
More informationScreening for ovarian cancer Kehoe, Sean
Screening for ovarian cancer Kehoe, Sean DOI: 10.1016/j.maturitas.2015.05.009 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation
More informationAccepted Manuscript. Current State of the Art for the Surgical Management of empyema thoracis. K. Robert Shen, M.D.
Accepted Manuscript Current State of the Art for the Surgical Management of empyema thoracis K. Robert Shen, M.D. PII: S0022-5223(18)32919-2 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.006 Reference:
More informationUniversal Screening for Lynch Syndrome in Women with Newly Diagnosed Endometrial Cancer
Universal Screening for Lynch Syndrome in Women with Newly Diagnosed Endometrial Cancer Sarah E. Ferguson, MD FRCSC; Divisions of Gynecologic Oncology UHN/MSH, Department of Obstetrics and Gynecology,
More informationColorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem
Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls Disclosures: None Jonathan P. Terdiman, M.D. Professor of Clinical Medicine University of California, San Francisco CRC: still a major public
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/22278 holds various files of this Leiden University dissertation. Author: Cunha Carvalho de Miranda, Noel Filipe da Title: Mismatch repair and MUTYH deficient
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationAuthor s Accepted Manuscript
Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Nitric Oxide: Might make it Better? J. Hunter Mehaffey, MD, MSc, Robert B. Hawkins, MD, MSc PII: S0022-5223(18)32342-0 DOI: 10.1016/j.jtcvs.2018.08.070 Reference: YMTC 13398 To appear
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More information2) Cases and controls were genotyped on different platforms. The comparability of the platforms should be discussed.
Reviewers' Comments: Reviewer #1 (Remarks to the Author) The manuscript titled 'Association of variations in HLA-class II and other loci with susceptibility to lung adenocarcinoma with EGFR mutation' evaluated
More informationThe Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto
Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationAccepted Manuscript. The readability of ipledge program patient education materials. Rachel Howard, BS, Gideon Smith, MD, PhD
Accepted Manuscript The readability of ipledge program patient education materials Rachel Howard, BS, Gideon Smith, MD, PhD PII: S0190-9622(18)30834-X DOI: 10.1016/j.jaad.2018.05.038 Reference: YMJD 12552
More informationEditorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD
Accepted Manuscript Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD PII: S0022-5223(18)33135-0 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.036
More information